Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsCash from RestructuringChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther financing activitiesOther financing activitiesShare-based CompensationShare-based Compensation
Growth Metrics
Income Statement
Others
Ratios

Lyra Therapeutics (LYRA) Gains from Investment Securities (2021 - 2025)

Lyra Therapeutics has reported Gains from Investment Securities over the past 5 years, most recently at $57716.0 for Q4 2025.

  • Quarterly results put Gains from Investment Securities at $57716.0 for Q4 2025, up 100.43% from a year ago — trailing twelve months through Dec 2025 was $57716.0 (down 42.28% YoY), and the annual figure for FY2025 was $57716.0, down 54.29%.
  • Gains from Investment Securities for Q4 2025 was $57716.0 at Lyra Therapeutics, down from $68558.0 in the prior quarter.
  • Over the last five years, Gains from Investment Securities for LYRA hit a ceiling of $13.7 million in Q1 2024 and a floor of -$13.6 million in Q4 2024.
  • Median Gains from Investment Securities over the past 5 years was $431489.0 (2023), compared with a mean of $1.1 million.
  • Biggest five-year swings in Gains from Investment Securities: soared 4244.88% in 2023 and later crashed 2253.49% in 2024.
  • Lyra Therapeutics' Gains from Investment Securities stood at $1.9 million in 2021, then tumbled by 97.54% to $45483.0 in 2022, then skyrocketed by 1285.13% to $630000.0 in 2023, then crashed by 2253.49% to -$13.6 million in 2024, then skyrocketed by 100.43% to $57716.0 in 2025.
  • The last three reported values for Gains from Investment Securities were $57716.0 (Q4 2025), $68558.0 (Q3 2025), and $3.0 million (Q1 2025) per Business Quant data.